Clinical trials: Neuroendocrine Neoplasms
Extraocular Extension Melanoma, Metastatic Intraocular Melanoma
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma
- Trial name
- NCT01533948
- Testing
- axitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Melanoma
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS).
- Trial name
- NCT05665595
- Testing
- Pembrolizumab/Vibostolimab, Pembrolizumab
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 1,594 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Trial of pIL-12 Electroporation Malignant Melanoma
This study will assess the safety and effectiveness of different dosing regimens of ImmunoPulse IL-12® in malignant melanoma. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene…
- Trial name
- IL-12MEL (NCT01502293)
- Testing
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- OncoSec Medical Incorporated
Melanoma (Skin)
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or…
- Trial name
- NCT00700882
- Testing
- dasatinib
- Where
- 153 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eastern Cooperative Oncology Group
Stage IIIB Melanoma, Stage IIIC Melanoma
Dinaciclib in Treating Patients With Stage III-IV Melanoma
This is a phase I/II trial is studying the side effects and best dose of dinaciclib and to see how well it works in treating patients with advanced melanoma.
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT01026324
- Testing
- dinaciclib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Neuroendocrine Tumors, Neuroendocrine Carcinoma
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Background: Neuroendocrine tumors (NETs) come from cells of the hormonal and nervous systems. Some people have surgery to shrink the tumor. Sometimes the tumors come back.
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Neoplasms, Carcinoma, Neuroendocrine
- Trial name
- NCT02315625
- Testing
- Sunitinib, Everolimus
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)
The purpose of this study is to characterize the pharmacokinetic (PK) profile of pembrolizumab (MK-3475) following single subcutaneous (SC) injection of pembrolizumab Dose A versus pembrolizumab Dose C in adults with advanced…
- Trial name
- NCT03665597
- Testing
- Pembrolizumab Dose C, Pembrolizumab Dose A, Pembrolizumab Dose B
- Where
- 15 sites in Australia, South Africa and 2 more
- Volunteers
- 138 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoid Syndrome, Carcinoid
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome.
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- NCT05361668
- Testing
- Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 36 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Melanoma and Metastatic Colorectal Cancer
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase…
- Trial name
- NCT01436656
- Testing
- LGX818
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 107 people
- Sponsor
- Pfizer
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
This phase II trial studies how well glembatumumab vedotin works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the body (metastatic) or has returned at or near…
- Trial name
- NCT02363283
- Testing
- Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 25 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma, Brain Metastases
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
This is a Phase 1 study of E6201 plus dabrafenib for the treatment of CNS metastases in BRAF V600-mutated metastatic melanoma. A total of up to N=28-34 subjects with melanoma metastasized to the CNS will be included.
- Trial name
- NCT03332589
- Testing
- E6201, E6201 plus dabrafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Spirita Oncology, LLC
Melanoma
Trial of Pembrolizumab and Radiotherapy in Melanoma
Around 13,000 participants are diagnosed with melanoma in the UK each year and that number is growing quicker than any other cancer.
- Trial name
- PERM (NCT02562625)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
The purpose of this study is to see whether a new type of anti-cancer drug, known as BAY 43-9006, can be given safely and with good effect in combination with dacarbazine (DTIC).
- Trial name
- NCT00492297
- Testing
- Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)
- Where
- 12 sites in France, United Kingdom
- Volunteers
- 83 people
- Sponsor
- Bayer
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT02178722
- Testing
- MK-3475, INCB024360
- Where
- 24 sites in United States
- Volunteers
- 444 people
- Sponsor
- Incyte Corporation
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is…
- Conditions
- Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
- Trial name
- NCT03991741
- Testing
- Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gregory Daniels
Unresected Stage IIIb to IVM1c Melanoma
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
The study is a phase 2, multi centered, single arm study designed to evaluate the correlation between cluster of differentiation 8-positive (CD8+) cell density and objective response rate in adults with unresected stage IIIB to…
- Trial name
- TVEC-325 (NCT02366195)
- Testing
- Talimogene Laherparepvec
- Where
- 42 sites in United States, Austria and 11 more
- Volunteers
- 112 people
- Sponsor
- Amgen
Neuroendocrine Tumors
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance…
- Trial name
- NCT03136328
- Testing
- 68Ga-DOTATOC
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
This phase I/II trial studies how well genetically modified therapeutic autologous lymphocytes (patient's own white blood cells) followed by aldesleukin work in treating patients with stage III melanoma or melanoma that has…
- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT01740557
- Testing
- Aldesleukin, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Neurofibromatosis 2, Vestibular Schwannoma
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
The purpose of this study is to determine if Lapatinib has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2). NF2 is a condition that mainly affects the skin and nervous system.
- Trial name
- NCT00973739
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health